陈健;纪志刚;

• 1:中国医学科学院北京协和医学院北京协和医院泌尿外科

摘要(Abstract)：

<正>肾细胞癌是泌尿外科常见肿瘤,从遗传学角度可分为散发性肾细胞癌和遗传性肾细胞癌,有遗传基础的肾细胞癌占所有肾细胞癌的5%[1]。遗传性肾细胞癌多并发全身其他组织脏器良性病变或恶性肿瘤,故称为肾细胞癌相关遗传综合征,各种肾细胞癌相关遗传性综合征均具有不同的突变基因、临床表现及病理类型。以往对肾细胞癌相关遗传性综合征的描述主要基于临床观察,如疾病的外在表现和家族遗传特点;近年来家系研究和分子遗传学进展为了解肾细胞癌相

关键词(KeyWords)： 肾细胞癌;遗传综合征

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈健;纪志刚;

Email:

DOI:

参考文献(References)：

• [1]Zbar B,Glenn G,Merino M,et al.Familial renal carcinoma:clinical evaluation,clinical subtypes and risk of renal carcinoma development[J].J Urol,2007,177:461-465.
• [2]Hwang JJ,Uchio EM,Linehan WM,et al.Hereditary kidney cancer[J].Urol Clin North Am,2003,30:831-842.
• [3]Courtney KD,Choueiri TK.Optimizing recent advances in metastatic renal cell carcinoma[J].Curr Oncol Rep,2009,11:218-226.
• [4]Dharmawardana PG,Giubellino A,Bottaro DP.Hereditary papillary renal carcinoma type I[J].Curr Mol Med,2004,4:855-868.
• [5]Schmidt LS,Nickerson ML,Angeloni D,et al.Early onset hereditary papillary renal carcinoma:germline missense mutations in the tyrosine kinase domain of the met proto-oncogene[J].J Urol,2004,172:1256-1261.
• [6]Herts BR,Coll DM,Novick AC,et al.Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys[J].AJR Am J Roentgenol,2002,178:367-372.
• [7]Herring JC,Enquist EG,Chernoff A,et al.Parenchymal sparing surgery in patients with hereditary renal cell carcinoma:10-year experience[J].J Urol,2001,165:777-781.
• [8]Srinivasan R,Choueiri T,Vaishampayan U,et al.A phaseⅡstudy of the dual MET/VEGFR2 inhibitor XL880 in patients(pts)with papillary renal carcinoma(PRC)(abstract)[J].J Clin Oncol,2008,26s:5103-5109.
• [9]Alam NA,Bevan S,Churchman M,et al.Localization of a gene(MCUL1)for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43[J].Am J Hum Genet,2001,68:1264-1269.
• [10]Pollard P,Wortham N,Barclay E,et al.Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome[J].J Pathol,2005,205:41-49.
• [11]Ooi A,Wong JC,Petillo D,et al.An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma[J].Cancer Cell,2011,20:511-523.
• [12]Sudarshan S,Sourbier C,Kong HS,et al.Fumaratehydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species[J].Mol Cell Biol,2009,29:4080-4090.
• [13]Grubb RL 3rd,Franks ME,Toro J,et al.Hereditary leiomyomatosis and renal cell cancer:a syndrome associated with an aggressive form of inherited renal cancer[J].J Urol,2007,177:2079-2080.
• [14]Sudarshan S,Pinto PA,Neckers L,et al.Mechanisms of disease:hereditary leiomyomatosis and renal cell cancer—a distinct form of hereditary kidney cancer[J].Nat Clin Pract Urol,2007,4:104-110.
• [15]Menko FH,van Steensel MA,Giraud S,et al.Birt-HoggDubésyndrome:diagnosis and management[J].Lancet Oncol,2009,10:1199-1206.
• [16]Schmidt LS,Nickerson ML,Warren MB,et al.Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubésyndrome[J].Am J Hum Genet,2005,76:1023-1033.
• [17]Vocke CD,Yang Y,Pavlovich CP,et al.High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors[J].J Natl Cancer Inst,2005,97:931-935.
• [18]Baba M,Hong SB,Sharma N,et al.Folliculin encoded by the BHD gene interacts with a binding protein,FNIP1,and AMPK,and is involved in AMPK and m TOR signaling[J].Proc Natl Acad Sci USA,2006,103:15552-15557.
• [19]Pavlovich CP,Walther MM,Eyler RA,et al.Renal tumors in the Birt-Hogg-Dubésyndrome[J].Am J Surg Pathol,2002,26:1542-1552.
• [20]Houweling AC,Gijezen LM,Jonker MA,et al.Renal cancer and pneumothorax risk in Birt-Hogg-Dubésyndrome;an analysis of 115 FLCN mutation carriers from 35 BHD families[J].Br J Cancer,2011,105:1912-1919.
• [21]Pavlovich CP,Grubb RL 3rd,Hurley K,et al.Evaluation and management of renal tumors in the Birt-Hogg-Dubésyndrome[J].J Urol,2005,173:1482-1486.
• [22]Barrisford GW,Singer EA,Rosner IL,et al.Familial renal cancer:molecular genetics and surgical management[J].Int J Surg Oncol,2011,2011:658767.
• [23]Baba M,Furihata M,Hong SB,et al.Kidney-targeted BirtHogg-Dube gene inactivation in a mouse model:Erk1/2 and Akt-m TOR activation,cell hyperproliferation,and polycystic kidneys[J].J Natl Cancer Inst,2008,100:140-154.
• [24]Neumann HP,Bausch B,Mc Whinney SR,et al.Germ-line mutations in nonsyndromic pheochromocytoma[J].N Engl J Med,2002,346:1459-1466.
• [25]Benn DE,Gimenez-Roqueplo AP,Reilly JR,et al.Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes[J].J Clin Endocrinol Metab,2006,91:827-836.
• [26]Young WF Jr,Abboud AL.Editorial:paraganglioma—all in the family[J].J Clin Endocrinol Metab,2006,91:790-792.
• [27]Ricketts CJ,Shuch B,Vocke CD,et al.Succinate dehydrogenase kidney cancer:an aggressive example of the Warburg effect in cancer[J].J Urol,2012,188:2063-2071.
• [28]Ricketts C,Woodward ER,Killick P,et al.Germline SDHB mutations and familial renal cell carcinoma[J].J Natl Cancer Inst,2008,100:1260-1262.
• [29]Dabora SL,Jozwiak S,Franz DN,et al.Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2,compared with TSC1,disease in multiple organs[J].Am J Hum Genet,2001,68:64-80.
• [30]El-Hashemite N,Zhang H,Henske EP,et al.Mutation in TSC2 and activation of mammalian target of rapamycinsignalling pathway in renal angiomyolipoma[J].Lancet,2003,361:1348-1349.
• [31]Rakowski SK,Winterkorn EB,Paul E,et al.Renal manifestations of tuberous sclerosis complex:Incidence,prognosis,and predictive factors[J].Kidney Int,2006,70:1777-1782.
• [32]Selle B,Furtwngler R,Graf N,et al.Population-basedstudy of renal cell carcinoma in children in Germany,1980-2005:more frequently localized tumors and underlying disorders compared with adult counterparts[J].Cancer,2006,107:2906-2614.
• [33]Kubo M,Iwashita K,Oyachi N,et al.Two different types of infantile renal cell carcinomas associated with tuberous sclerosis[J].J Pediatr Surg,2011,46:E37-E41.
• [34]Paul E,Thiele EA,Shailam R,et al.Case records of the Massachusetts General Hospital.Case 26-2011.A 7-year-old boy with a complex cyst in the kidney[J].N Engl J Med,2011,365:743-751.
• [35]Lonser RR,Glenn GM,Walther M,et al.von Hippel-Lindau disease[J].Lancet,2003,361:2059-2067.
• [36]Barry RE,Krek W.The von Hippel-Lindautumour suppressor:a multi-faceted inhibitor of tumourigenesis[J].Trends Mol Med,2004,10:466-472.
• [37]Lonser RR,Glenn GM,Walther M,et al.von Hippel-Lindau disease[J].Lancet,2003,361:2059-2067.
• [38]Jonasch E,Mc Cutcheon IE,Waguespack SG,et al.Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease[J].Ann Oncol,2011,22:2661-2666.